Low dose, short-term rivastigmine administration does not affect neurocognition in methamphetamine dependent individuals

► This is the first study, to our knowledge, to examine whether a cholinesterase inhibitor can improve neurocognitive functioning in methamphetamine dependent individuals. ► Short-term, low-dose rivastigmine administration does not improve neurocognition in methamphetamine dependent individuals. ► The methodology was sufficiently rigorous to detect such effects, i.e., within-subjects, double-blind, placebo control. ► Given the results of studies in other populations, higher dosing over a longer period of time would be most likely to yield a positive effect. ► This study further demonstrates that rivastigmine can be safely administered to methamphetamine dependent individuals without adverse effects.